BR112017015013A2 - anti-histamina para uso no tratamento de câncer da mama - Google Patents

anti-histamina para uso no tratamento de câncer da mama

Info

Publication number
BR112017015013A2
BR112017015013A2 BR112017015013A BR112017015013A BR112017015013A2 BR 112017015013 A2 BR112017015013 A2 BR 112017015013A2 BR 112017015013 A BR112017015013 A BR 112017015013A BR 112017015013 A BR112017015013 A BR 112017015013A BR 112017015013 A2 BR112017015013 A2 BR 112017015013A2
Authority
BR
Brazil
Prior art keywords
breast cancer
antihistamine
cancer treatment
ebastine
desloratadine
Prior art date
Application number
BR112017015013A
Other languages
English (en)
Inventor
Olsson Håkan
Einefors Rickard
Original Assignee
Belina Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belina Pharma Ab filed Critical Belina Pharma Ab
Publication of BR112017015013A2 publication Critical patent/BR112017015013A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

é aqui divulgada desloratadina ou ebastina para uso no tratamento de um paciente diagnosticado com câncer de mama. também é divulgada desloratadina ou ebastina para uso no tratamento de um paciente diagnosticado com um tipo de câncer suscetível à imunoterapia.
BR112017015013A 2015-01-19 2016-01-19 anti-histamina para uso no tratamento de câncer da mama BR112017015013A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1550036 2015-01-19
PCT/EP2016/051000 WO2016116438A1 (en) 2015-01-19 2016-01-19 Antihistamine for use in treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112017015013A2 true BR112017015013A2 (pt) 2018-01-23

Family

ID=55174654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017015013A BR112017015013A2 (pt) 2015-01-19 2016-01-19 anti-histamina para uso no tratamento de câncer da mama

Country Status (15)

Country Link
US (1) US10456388B2 (pt)
EP (1) EP3247356B1 (pt)
JP (1) JP6745805B2 (pt)
KR (1) KR102387840B1 (pt)
CN (1) CN107249587B (pt)
AU (1) AU2016208673B2 (pt)
BR (1) BR112017015013A2 (pt)
CA (1) CA2973913C (pt)
ES (1) ES2841981T3 (pt)
IL (1) IL253533B (pt)
MX (1) MX2017009281A (pt)
PL (1) PL3247356T3 (pt)
RU (1) RU2017129056A (pt)
WO (1) WO2016116438A1 (pt)
ZA (1) ZA201704634B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154260A1 (en) 2019-10-18 2021-04-22 Belina Pharma Ab Medicament for treatment and/or prophylactic treatment of cancers
WO2021137935A2 (en) * 2019-11-04 2021-07-08 University Of Kentucky Research Foundation Novel superebastine against therapy resistant prostate cancer
CN110755431B (zh) * 2019-11-08 2023-02-28 暨南大学 地氯雷他定在制备抗肝癌药物中的应用
WO2022055408A1 (en) 2020-09-10 2022-03-17 Belina Pharma Ab Desloratadine or loratadine for use in the treatment of breast cancer
CN114432446B (zh) * 2020-11-05 2023-07-04 南湖实验室 抗组胺药在制备抗肿瘤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
FR2825279B1 (fr) 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
US20040072824A1 (en) 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
US20050119263A1 (en) 2001-11-09 2005-06-02 Vincent Mark D. Treatment of breast cancer
EP1656124A1 (en) 2003-03-12 2006-05-17 Cerenis Methods and compositions for the treatment of cancer
MX2007008843A (es) * 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
US20130263297A1 (en) * 2010-11-10 2013-10-03 Cedars-Sinai Medical Center Methods of treating cancer
RU2490028C1 (ru) 2012-01-26 2013-08-20 Михаил Аркадьевич Шурдов Способ лечения онкологических заболеваний
WO2014018563A2 (en) 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
CN103830208A (zh) * 2012-11-26 2014-06-04 天津金耀集团有限公司 含有h1受体拮抗剂的吸入制剂
CN103044395B (zh) * 2012-12-31 2015-03-11 天津药物研究院 含有地氯雷他定结构的氨基酸类衍生物、其制备方法和用途
CN104292211A (zh) 2013-07-15 2015-01-21 天津药物研究院 地氯雷他定类一氧化氮供体及其制备方法和用途

Also Published As

Publication number Publication date
WO2016116438A1 (en) 2016-07-28
JP6745805B2 (ja) 2020-08-26
PL3247356T3 (pl) 2021-05-04
ES2841981T3 (es) 2021-07-12
EP3247356A1 (en) 2017-11-29
US20180008588A1 (en) 2018-01-11
KR102387840B1 (ko) 2022-04-18
CA2973913C (en) 2021-12-14
JP2018502125A (ja) 2018-01-25
US10456388B2 (en) 2019-10-29
ZA201704634B (en) 2021-06-30
KR20170104499A (ko) 2017-09-15
CN107249587B (zh) 2021-04-23
EP3247356B1 (en) 2020-10-07
RU2017129056A (ru) 2019-02-21
AU2016208673A1 (en) 2017-09-07
RU2017129056A3 (pt) 2019-07-17
AU2016208673B2 (en) 2021-04-01
IL253533B (en) 2022-02-01
MX2017009281A (es) 2018-02-09
CA2973913A1 (en) 2016-07-28
IL253533A0 (en) 2017-09-28
CN107249587A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
BR112017023269A2 (pt) métodos para tratamento de câncer
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
HK1247129A1 (zh) 治療癌症的聯合療法
EP3222278C0 (en) USE OF AZELNIDIPINE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION INDICATED FOR THE TREATMENT OF CANCER
KR20180084772A (ko) 암 치료를 위한 조합 치료법
BR112017015013A2 (pt) anti-histamina para uso no tratamento de câncer da mama
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112016025470A2 (pt) ?hdl terapêutico?
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
IL262121A (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
IL276733A (en) Use of Aribolin in cancer treatment
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
ZA201802452B (en) New therapeutic strategies against blood cancer
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
UY36286A (es) Tratamientos médicos basados en anamorelina
EA201790990A1 (ru) Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге
IL258494A (en) Rational combined therapy for cancer treatment
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]